NCT03632031 is a NA clinical trial of Oasis Extracellular Matrix in Non-healing Wound, sponsored by Cook Biotech Incorporated.

Who is sponsoring NCT03632031?

NCT03632031 is sponsored by Cook Biotech Incorporated.

What drugs are being tested in NCT03632031?

Interventions in NCT03632031: Oasis Extracellular Matrix, Standard Care (in control arm).

What condition does NCT03632031 study?

NCT03632031 studies Non-healing Wound.

Is NCT03632031 still recruiting?

NCT03632031 is currently completed. Last updated 18 February 2026.

Last reviewed 2026-02-18 · How we verify

NCT03632031

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Wounds Using Oasis® ECM

Completed NA Last updated 18 February 2026

What this trial tests

NA trial testing Oasis Extracellular Matrix in Non-healing Wound in 41 participants. Completed in 26 September 2025.

Timeline

1 March 2021

Primary endpoint
1 March 2025

26 September 2025

Quick facts

Lead sponsor	Cook Biotech Incorporated
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	1 March 2021
Primary completion	1 March 2025
Estimated completion	26 September 2025
Sites	2 locations across United Kingdom

Drugs / interventions tested

Oasis Extracellular Matrix
Standard Care (in control arm) — full drug profile →

Conditions studied

Non-healing Wound — all drugs for Non-healing Wound →

Sponsor

Cook Biotech Incorporated

Who can join

18 and older, any sex, with Non-healing Wound. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical study is to gather post-market clinical evidence on the use of Oasis ECM as a treatment for donor site wounds in the community setting in the United Kingdom.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products.
Sharma A, Sharma D, Zhao F. · · 2023 · cited 29× · PMID 37306401 · DOI 10.1002/adhm.202300556

Verify or expand the search:

Other recruiting trials for Non-healing Wound

Currently open trials in the same condition.

NCT06327113 — Antibiotic Tumescent For Chronic Wounds · Phase 2 · recruiting
NCT05739149 — A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers · NA · recruiting

Other Cook Biotech Incorporated trials

Trials by the same sponsor.

NCT04294446 — Post-market Study of the Biodesign Hernia Graft · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03632031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cook Biotech Incorporated
Last refreshed: 18 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing